Sunday, October 4, 2026

USD/EUR Bearish Momentum With A 1% Slide In The Last 10 Sessions

ViaNews Editorial Team

December 21, 2023

USD/EUR Bearish Momentum With A 1% Slide In The Last 10 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.98% for the last 10 sessions. At 16:08 EST on Thursday, 21 December, USD/EUR (USDEUR) is $0.91.

USD/EUR's yearly highs and lows, it's 2.65% up from its 52-week low and 4.869% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.22%, a negative 0.02%, and a positive 0.34%, respectively.

USD/EUR's highest amplitude of average volatility was 0.67% (last week), 0.38% (last month), and 0.34% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy corrects from 145.00 as fed’s rate cut expectations soar. According to FXStreet on Wednesday, 20 December, "The USD/JPY pair corrects to near 143.50 amid expectations that the Federal Reserve (Fed) will start lowering borrowing interest rates earlier than projected by policymakers. "
  • Usd/jpy swamped near 144.00 after failing to vault over 145.00 on Tuesday. According to FXStreet on Tuesday, 19 December, "Intraday action finds the USD/JPY pinned into the 200-day Simple Moving Average (SMA) near the 144.00 handle, after hitting a Tuesday high that fell just shy of the 145.00 major price level.", "Daily candlesticks show the USD/JPY churning at the 200-day SMA as medium-term momentum drains out of the pair, leaving bids to waffle into long-term median prices."
  • Usd/jpy: boj puts the fate of the yen in the hands of the fed or the dollar – commerzbank. According to FXStreet on Tuesday, 19 December, "In other words, in the end, it will never be about Yen strength, but always about Dollar weakness when USD/JPY falls (for example, because Fed rate cut expectations are rising, as is the case now). "
  • Usd/jpy: the pace of depreciation will be gradual in the near term, decisive break below 140 in 2Q24 – ING. According to FXStreet on Tuesday, 19 December, "We remain bearish on USD/JPY in 2024, as the oversold Yen can still benefit from the end of negative rates in Japan and we see the Fed cut rates by 150 bps, but the pace of depreciation in the pair will be gradual in the near term, and we only see a decisive break below 140 in 2Q24."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com